Change in patient-reported outomes over time from breast cancer diagnosis.

Authors

null

C. E. Hill-Kayser

Hospital of the University of Pennsylvania, Philadelphia, PA

C. E. Hill-Kayser , C. Vachani , M. K. Hampshire , G. A. Di Lullo , J. M. Metz

Organizations

Hospital of the University of Pennsylvania, Philadelphia, PA, University of Pennsylvania, Philadelphia, PA

Research Funding

No funding sources reported

Background: Breast cancer survivors may be at risk for significant late effects after treatment. Understanding the patterns of change over time of patient reported outcomes (PRO) is often very challenging. Methods: Patient-reported data was gathered via a convenience sample frame from breast cancer survivors utilizing a publically available, free, Internet-based tool for creation of survivorship care plans. Available at www.livestrongcareplan.com and through the OncoLink website, the tool allows survivors to enter data regarding diagnosis, demographics, treatments received, and late effects experienced, and provides them with customized guidelines for future care. All data has been maintained anonymously with IRB approval. Results: 1,145 breast cancer survivors were queried with regard to PRO. Median age at diagnosis (dx) was 49 yrs, and median current age 52 yrs. Of users, 98% reported having had surgery; of these 56% underwent mastectomy and 49% lumpectomy (5% both). Similarly, 59% underwent sentinel LN biopsy, and 47% axilary dissection. Of the same cohort, 88% received chemotherapy and/or hormonal treatment, and 70% radiation therapy. The median time from dx until use of the care plan tool was 2 years (range 0-33 years). Late effects reported by survivors ≤ 2 and > 2 years from diagnosis are shown (see table). Overall, survivors ≤ 2 years from dx were more likely to note changes in skin color or texture; those > 2 years from diagnosis were more likely to note osteopenia, lymphedema, and sexual changes. Patient reported cognitive changes, arm pain/numbness/tingling, and loss of shoulder flexibility did not differ between the two groups. Conclusions: This anonymous tool uses a convenience sample frame to gather PRO after breast cancer diagnosis/ treatment. PRO varied significantly with time since dx, with more late effects reported > 2 years from dx. This information may be of use during patient counseling and survivorship care delivery.


PRO Early (≤ 2 years from Dx)
n = 715
Late (> 2 years from Dx)
n = 430
p value

Osteoporosis/penia 21% 43% < 0.001
Cognitive changes 64% 63% 0.98
Lymphedema 30% 34% < 0.001
Arm pain/numbness/tingling 56% 60% 0.2
Skin color/ texture change 60% 49% 0.001
Loss of shoulder flexibility 31% 36% 0.3
Sexual changes 45% 62% < 0.001

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2011 Breast Cancer Symposium

Session Type

Poster Session

Session Title

General Poster Session C

Track

Prevention, Survivorship & Health Policy

Sub Track

Health Services Research

Citation

J Clin Oncol 29, 2011 (suppl 27; abstr 210)

Abstract #

210

Poster Bd #

C24

Abstract Disclosures

Similar Abstracts

Abstract

2024 ASCO Annual Meeting

Timeframe for lymphedema therapy for head and neck cancer survivors.

First Author: Cristina Kline-Quiroz

Abstract

2023 ASCO Quality Care Symposium

Demand for oncology visits among low-risk breast cancer survivors.

First Author: Emily H. Douglas

First Author: Laura LaNiel Tenner